Live Chat

KPNC Study Sees Significant Risk for Some Pioglitazone Patients

An interim analysis earlier this year of Kaiser Permanente Northern California’s (KPNC) five-year study revealed that diabetes patients who took an Actos (pioglitazone) treatment for longer than one year were at a considerably greater risk of developing bladder cancer. Treatments lasting less than one year imposed no significant risk, however, Actos (pioglitazone) treatments beyond one year increased the risk of bladder cancer by a remarkable 40 percent.

 The risk of bladder cancer associated with Actos (pioglitazone) was so great, in fact, that the French Medicines Agency suspended the use of pioglitazone-based prescriptions this summer. In the United States, the Food and Drug Administration (FDA) has emphasized the very real risk of pioglitazone treatments, but has stopped short of prohibiting this dangerous drug.

 Fears Nachawati protects the rights of bladder cancer patients injured by Actos and other pioglitazone-based medications. If you’re suffering from bladder cancer, your rights may have been violated. To find out what you need to know about your medical options, contact us immediately. For a free consultation, call us at 1.866.545.8364 or email We’re ready to fight for you!

Drug Litigation

KPNC Study Sees Significant Risk for Some Pioglitazone Patients